LB1148 for Ileus

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Site 319, Houston, TX
Ileus+4 More
LB1148 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.

Eligible Conditions

  • Ileus
  • Gastrointestinal Disorder

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: From surgical procedure up to 14 days in hospital

Day 14
Time discharge order written
Time of actual discharge
Time subject is ready for discharge
Time to first bowel movement
Time to return of gastrointestinal function

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

LB1148
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

600 Total Participants · 2 Treatment Groups

Primary Treatment: LB1148 · Has Placebo Group · Phase 3

LB1148
Drug
Experimental Group · 1 Intervention: LB1148 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LB1148
2019
Completed Phase 2
~140

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from surgical procedure up to 14 days in hospital
Closest Location: Site 319 · Houston, TX
Photo of Houston 1Photo of Houston 2Photo of Houston 3
2008First Recorded Clinical Trial
2 TrialsResearching Ileus
2 CompletedClinical Trials

Who is running the clinical trial?

Palisade BioLead Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled
1 Trials studying Ileus
200 Patients Enrolled for Ileus

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are scheduled to undergo a planned (non-emergent) bowel resection via minimally invasive technique or laparotomy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.